ClinicalTrials.gg
CompletedNCT00838201Updated Oct 18, 2018Results posted

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

A Phase 3 interventional study of Denosumab in Cancer, Carcinoma and Castrate-Resistant Prostate Cancer, sponsored by Amgen. Completed at 74 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
384
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

The purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3 years under the 20040138 Amgen study and 2 years on this study) denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab for non-metastatic prostate cancer.

02

Conditions studied

  • Cancer
  • Carcinoma
  • Castrate-Resistant Prostate Cancer
  • Prostate Cancer
  • Tumors

Keywords

  • Androgen deprivation therapy for non-metastatic prostate cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 384 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be currently participating in the 20040138 Amgen study
  • Subjects must sign the before any study specific procedures are performed.

Exclusion criteria

Exclusion Criteria

  • Subjects with any prior diagnosis of bone
  • Known hypocalcemia
  • Developed sensitivity to mammalian cell derived drug products during the 20040138 study
  • Currently receiving any product other than denosumab or having received any investigational product during the 20040138 study
  • Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written and/or comply with study procedures
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
384 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Denosumab

Interventions

  • 60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18

06

What researchers measure

Primary outcomes

  1. Overall Survival Through Month 24

    Time frame: 24 months

07

Results

Posted Sep 24, 2013

Participant flow

First subject enrollment date: 18 February 2009; Last subject enrollment date: 11 May 2010

Participant flow — Overall Study
MilestonePlacebo/Denosumab 60 mg SC Q6MDenosumab/Denosumab 60 mg SC Q6M
Started186198
Completed144145
Not completed4253
Withdrew: Investigator decision, or other reasons23
Withdrew: Noncompliance01
Withdrew: Administrative decision12
Withdrew: Disease progression33
Withdrew: Consent withdrawn1619
Withdrew: Lost to follow-up43
Withdrew: Adverse event59
Withdrew: Death1113

Outcome measures

PrimaryOverall Survival Through Month 24
Time frame:
24 months
Reported as:
Number · Participants
Overall Survival Through Month 24
ParticipantsPlacebo/Denosumab 60 mg SC Q6MDenosumab/Denosumab 60 mg SC Q6M
Overall Survival Through Month 24174184

Adverse events

Collected over about 38 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/ Denosumab 60 mg Q6M—45/185 (24.3%)47/185 (25.4%)
Denosumab/ Denosumab 60 mg Q6M—51/199 (25.6%)46/199 (23.1%)
Most frequent serious events
Showing 10 of 138
Most frequent serious events
EventPlacebo/ Denosumab 60 mg Q6MDenosumab/ Denosumab 60 mg Q6M
Cardiac failure congestiveCardiac disorders5/1850/199
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1852/199
Cerebrovascular accidentNervous system disorders3/1852/199
Respiratory failureRespiratory, thoracic and mediastinal disorders3/1850/199
HaematuriaRenal and urinary disorders1/1853/199
AnaemiaBlood and lymphatic system disorders2/1852/199
CellulitisInfections and infestations2/1851/199
Clostridium difficile colitisInfections and infestations2/1851/199
PneumoniaInfections and infestations2/1852/199
DehydrationMetabolism and nutrition disorders2/1850/199
Most frequent other events
Most frequent other events
EventPlacebo/ Denosumab 60 mg Q6MDenosumab/ Denosumab 60 mg Q6M
ConstipationGastrointestinal disorders16/18513/199
ArthralgiaMusculoskeletal and connective tissue disorders12/18510/199
Urinary tract infectionInfections and infestations6/18512/199
Pain in extremityMusculoskeletal and connective tissue disorders11/1859/199
NauseaGastrointestinal disorders8/18511/199
Back painMusculoskeletal and connective tissue disorders8/18511/199

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo/Denosumab 60 mg SC Q6MDenosumab/Denosumab 60 mg SC Q6MTotal
Mean73 ± 7.174.1 ± 6.673.6 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/Denosumab 60 mg SC Q6MDenosumab/Denosumab 60 mg SC Q6MTotal
Female000
Male186198384
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/Denosumab 60 mg SC Q6MDenosumab/Denosumab 60 mg SC Q6MTotal
White or Caucasian153173326
Black or African American6814
Hispanic or Latino261743
Japanese101
08

Study locations

74 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Laguna Hills, California 92653, United States
  • Research Site
    Long Beach, California 90813, United States
  • Research Site
    San Bernardino, California 92404, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Middlebury, Connecticut 06762, United States
  • Research Site
    New Britain, Connecticut 06052, United States
  • Research Site
    Trinity, Florida 34655, United States
  • Research Site
    Fort Wayne, Indiana 46825, United States
  • Research Site
    Greenbelt, Maryland 20770, United States
  • Research Site
    Sartell, Minnesota 56377, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Bay Shore, New York 11706, United States
  • Research Site
    Garden City, New York 11530, United States
  • Research Site
    Poughkeepsie, New York 12601, United States
  • Research Site
    Lancaster, Pennsylvania 17604, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Salem, Virginia 24153, United States
  • Research Site
    Burien, Washington 98166, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Calgary, Alberta T2V 1P9, Canada
  • Research Site
    Kelowna, British Columbia V1Y 2H4, Canada
  • Research Site
    Surrey, British Columbia V3V 1N1, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Victoria, British Columbia V8T 5G1, Canada
  • Research Site
    Victoria, British Columbia V8V 3N1, Canada
  • Research Site
    Barrie, Ontario L4M 7G1, Canada
  • Research Site
    Brantford, Ontario N3R 4N3, Canada
  • Research Site
    Burlington, Ontario L7N 3V2, Canada
  • Research Site
    Burlington, Ontario L7S 1V2, Canada
  • Research Site
    Guelph, Ontario N1H 5J1, Canada
  • Research Site
    Kingston, Ontario K7L 3J7, Canada
  • Research Site
    Kitchener, Ontario N2N 2B9, Canada
  • Research Site
    London, Ontario N6A 4G5, Canada
  • Research Site
    Markham, Ontario L6B 1A1, Canada
  • Research Site
    Newmarket, Ontario L3X 1W1, Canada
  • Research Site
    North Bay, Ontario P1B 7K8, Canada
  • Research Site
    North York, Ontario M2J 1V1, Canada
  • Research Site
    Oakville, Ontario L6H 3P1, Canada
  • Research Site
    Oshawa, Ontario L1H 7K4, Canada
  • Research Site
    Scarborough, Ontario M1P 2T7, Canada
  • Research Site
    Sudbury, Ontario P3E 4T3, Canada
  • Research Site
    Toronto, Ontario M2J 1V1, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M6A 3B5, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H3, Canada
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
  • Research Site
    Seinajoki, 60220, Finland
  • Research Site
    Tampere, 33520, Finland
  • Research Site
    Balatonfured, 8230, Hungary
  • Research Site
    Budapest, 1036, Hungary
  • Research Site
    Budapest, 1204, Hungary
  • Research Site
    Gyor, 9023, Hungary
  • Research Site
    Nyiregyhaza, 4400, Hungary
  • Research Site
    Mexico City, Distrito F 07760, Mexico
  • Research Site
    Mexico City, Distrito F 14140, Mexico
  • Research Site
    Toluca, 50120, Mexico
  • Research Site
    Veracruz, 91700, Mexico
  • Research Site
    Bialystok, 15-276, Poland
  • Research Site
    Bydgoszcz, 85-171, Poland
  • Research Site
    Lublin, 20-718, Poland
  • Research Site
    Lublin, 20-954, Poland
  • Research Site
    Opole, 45-086, Poland
  • Research Site
    Siedlce, 08-110, Poland
  • Research Site
    Warszawa, 00-416, Poland
  • Research Site
    Warszawa, 02-781, Poland
  • Research Site
    Wroclaw, 50-088, Poland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in May 2012, 39 months.

Results were first posted in Sep 2013, 1 year 4 months after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 39 months is below that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2009
First posted
Feb 6, 2009
StartActual
Feb 1, 2009
Primary completionActual
May 3, 2012
CompletionActual
May 3, 2012
Results first posted
Sep 24, 2013
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00838201
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 6, 2009
Start date
Feb 1, 2009
Primary completion
May 3, 2012
Completion
May 3, 2012
Results posted
Sep 24, 2013
Last update
Oct 18, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion